RB Capital Management LLC Raises Stock Holdings in Pfizer Inc. (NYSE:PFE)

RB Capital Management LLC raised its stake in Pfizer Inc. (NYSE:PFEGet Rating) by 17.4% during the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 6,391 shares of the biopharmaceutical company’s stock after acquiring an additional 945 shares during the period. RB Capital Management LLC’s holdings in Pfizer were worth $335,000 as of its most recent SEC filing.

A number of other institutional investors have also recently modified their holdings of PFE. Norges Bank purchased a new stake in shares of Pfizer in the fourth quarter worth $3,351,891,000. Capital International Investors grew its stake in shares of Pfizer by 3,059.6% in the first quarter. Capital International Investors now owns 38,530,003 shares of the biopharmaceutical company’s stock worth $1,994,698,000 after acquiring an additional 37,310,556 shares during the last quarter. Vanguard Group Inc. grew its stake in shares of Pfizer by 3.0% in the first quarter. Vanguard Group Inc. now owns 479,065,273 shares of the biopharmaceutical company’s stock worth $24,801,210,000 after acquiring an additional 13,790,348 shares during the last quarter. DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main grew its stake in shares of Pfizer by 577.8% in the fourth quarter. DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main now owns 12,247,903 shares of the biopharmaceutical company’s stock worth $715,270,000 after acquiring an additional 10,440,786 shares during the last quarter. Finally, Massachusetts Financial Services Co. MA grew its stake in shares of Pfizer by 28.2% in the first quarter. Massachusetts Financial Services Co. MA now owns 43,391,119 shares of the biopharmaceutical company’s stock worth $2,246,359,000 after acquiring an additional 9,537,621 shares during the last quarter. 67.90% of the stock is owned by hedge funds and other institutional investors.

Pfizer Price Performance

NYSE:PFE opened at $44.57 on Friday. Pfizer Inc. has a 12 month low of $40.94 and a 12 month high of $61.71. The stock has a 50 day moving average of $48.40 and a two-hundred day moving average of $50.33. The company has a current ratio of 1.42, a quick ratio of 1.20 and a debt-to-equity ratio of 0.39. The firm has a market cap of $250.14 billion, a P/E ratio of 8.72, a price-to-earnings-growth ratio of 0.54 and a beta of 0.70.

Pfizer (NYSE:PFEGet Rating) last posted its quarterly earnings data on Thursday, July 28th. The biopharmaceutical company reported $2.04 EPS for the quarter, topping the consensus estimate of $1.95 by $0.09. Pfizer had a return on equity of 43.18% and a net margin of 28.92%. The company had revenue of $27.74 billion during the quarter, compared to analyst estimates of $26.20 billion. During the same period in the previous year, the business earned $1.07 EPS. Pfizer’s quarterly revenue was up 46.8% on a year-over-year basis. On average, analysts expect that Pfizer Inc. will post 6.54 earnings per share for the current fiscal year.

Pfizer Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Monday, December 5th. Stockholders of record on Friday, November 4th will be given a $0.40 dividend. This represents a $1.60 dividend on an annualized basis and a dividend yield of 3.59%. Pfizer’s dividend payout ratio (DPR) is presently 31.31%.

Wall Street Analysts Forecast Growth

A number of research analysts have recently issued reports on the company. SVB Leerink lowered their price target on Pfizer from $55.00 to $53.00 and set a “market perform” rating on the stock in a report on Friday, July 29th. Barclays set a $50.00 target price on Pfizer in a report on Thursday, September 1st. Morgan Stanley lowered their target price on Pfizer from $52.00 to $49.00 and set an “equal weight” rating on the stock in a report on Friday, July 8th. The Goldman Sachs Group set a $50.00 price objective on Pfizer in a research note on Thursday, September 1st. Finally, Berenberg Bank set a $44.00 price objective on Pfizer in a research note on Wednesday, September 14th. Nine investment analysts have rated the stock with a hold rating, ten have given a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $57.00.

About Pfizer

(Get Rating)

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women's health under the Premarin family and Eliquis brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines, and oral COVID-19 treatment under the Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, Panzyga, and Paxlovid brands.

See Also

Institutional Ownership by Quarter for Pfizer (NYSE:PFE)

Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.